Zura Bio Ltd

Zura Bio Ltd, a clinical-stage biopharmaceutical company focused on immunology and rare disease, filed an amended quarterly report on Form 10-Q/A with the SEC on April 25, 2022, bearing accession number 0001410578-22-001001 and registered under CIK 0001855644. The company entered the public markets through a SPAC merger and operates in the life sciences sector, developing targeted therapies for immune-mediated conditions. The 10-Q/A represents a formal amendment to a previously submitted quarterly disclosure, indicating updated or restated financial or operational information for the relevant period. Visit SpacDesk and sign up for full filing history, merger timelines, and data coverage on Zura Bio and hundreds of other SPAC-linked companies.